TREM2–ERK/p38 Axis in Microglial Regulation During Autoimmune Uveitis

Study Background and Research Question

Uveitis, an umbrella term for intraocular inflammatory disorders, contributes significantly to global visual impairment, accounting for up to 20% of cases according to recent epidemiological surveys. The non-infectious forms, such as Vogt-Koyanagi-Harada (VKH) disease, are typically mediated by autoimmune responses involving complex immune cell interactions. While T helper (Th) cell imbalances—specifically, increased Th1/Th17 and reduced regulatory T (Treg) cell proportions—are established features of uveitic pathology, the upstream molecular regulators within the retinal microenvironment are insufficiently understood. Microglia, the resident immune sentinels of the retina, are increasingly recognized for their role in orchestrating these immune dynamics, yet the precise signaling pathways mediating their activation in autoimmune uveitis remain to be fully elucidated.

Key Innovation from the Reference Study

The reference study by Yu et al. (Invest Ophthalmol Vis Sci. 2026) delivers a critical advance by identifying the trigger receptor expressed on myeloid cell 2 (TREM2) as a pivotal modulator of microglial activation in experimental autoimmune uveitis (EAU). Through integrative molecular and cellular approaches, the research clarifies that TREM2 restrains microglial-driven inflammation primarily via suppression of the ERK and p38 signaling arms of the mitogen-activated protein kinase (MAPK) pathway. This anti-inflammatory axis not only modulates local retinal immune responses but also alters systemic T cell polarization profiles, positioning TREM2 as a potential therapeutic node in autoimmune ocular disease.

Methods and Experimental Design Insights

The study implemented both in vivo and in vitro approaches to dissect TREM2’s influence on microglial activation and retinal inflammation. Key methodological steps included:

• EAU Mouse Model: Induction of autoimmune uveitis in mice, with subsequent assessment of retinal inflammation and vascular leakage.
• BV2 Microglial Cell Assays: Use of the BV2 cell line to model microglial inflammatory responses in vitro, with targeted TREM2 knockdown and overexpression strategies.
• Molecular Analyses: Quantification of TREM2 expression at various disease stages by RT-qPCR, coupled with Western blotting, enzyme-linked immunosorbent assay (ELISA), and flow cytometry to assess downstream immune phenotypes.
• Signaling Pathway Profiling: Western blot and RNA sequencing (RNA-seq) were employed to monitor activation states of MAPK components—specifically ERK and p38—in response to TREM2 modulation.
• Immune Cell Profiling: Flow cytometric analysis of splenic T cell subsets (Th1, Th17, Treg) to capture systemic immune alterations.

This multifaceted approach ensured robust interrogation of both cell-intrinsic signaling and whole-organism immune outcomes, aligning mechanistic findings with physiologically relevant disease models.

Core Findings and Why They Matter

Yu et al. reported several interlinked discoveries:

• TREM2 Expression Dynamics: TREM2 levels in retinal tissue rose during peak EAU inflammation and declined during disease resolution, implicating temporal regulation in disease pathogenesis.
• Microglial Activation and Inflammation: TREM2 knockdown in microglia led to heightened inflammatory cytokine production and exacerbated retinal pathology, whereas TREM2 overexpression conferred anti-inflammatory effects.
• Signaling Pathway Dependency: Mechanistically, TREM2 suppressed ERK and p38 MAPK phosphorylation. Loss of TREM2 disinhibited these pathways, amplifying pro-inflammatory signaling cascades.
• Systemic Immune Modulation: In EAU mice, TREM2 knockout increased proportions of splenic Th1 and Th17 cells—both drivers of autoimmunity—while reducing Treg populations, suggesting broader immunoregulatory roles beyond the retina.
• Transcriptomic Shifts: RNA-seq analysis revealed that TREM2 deficiency reshaped the retinal transcriptome, particularly upregulating MAPK-associated inflammatory genes.

Together, these data position TREM2 as a negative regulator of microglial-driven inflammation in EAU, acting through direct inhibition of ERK/p38 signaling. This insight advances current understanding of immune response modulation in dendritic cells and microglia, offering a framework for targeting retinal autoimmunity with molecular precision.

Comparison with Existing Internal Articles

Several internal resources highlight the broader landscape of immune modulation tools and their relevance to autoimmune modeling:

• The article "Pertussis Toxin: Mechanisms and Innovations in Immune Modulation" explores the AB5-type protein exotoxin pertussis toxin as a benchmark for dissecting cAMP-dependent immune modulation in vitro and in vivo. While the reference study centers on endogenous regulatory proteins (TREM2), the internal article contextualizes how exogenous modulators like pertussis toxin can shape dendritic cell maturation, cAMP signaling, and T-cell polarization—complementing the mechanistic focus on microglia and MAPK pathways.
• "Pertussis Toxin: Optimizing Immune Modulation Workflows" details workflow optimizations and troubleshooting for using pertussis toxin in TH17 differentiation and autoimmune modeling. This resonates with the reference study’s findings on T cell subset imbalances in uveitis, supporting the translational value of both molecular and pharmacological immune modulation strategies.
• Other resources, such as "Applied Insights: Pertussis Toxin for Immune Modulation Studies", extend these themes by providing practical guidance for signal transduction assays, further bridging the gap between molecular mechanisms and experimental application.

Collectively, these internal articles provide practical extension points for researchers looking to operationalize findings from TREM2–MAPK axis studies using well-characterized immunomodulatory agents such as pertussis toxin.

Limitations and Transferability

While the reference study delivers mechanistic clarity, several important limitations should be noted:

• Model Specificity: Findings are derived from murine EAU models and immortalized BV2 microglial cells, which may not fully replicate human uveitic pathology or primary cell behavior.
• Temporal Resolution: TREM2’s expression and function were profiled at discrete disease stages; continuous or longitudinal analysis might reveal additional regulatory dynamics.
• Pathway Breadth: The focus was on ERK/p38 MAPK signaling, but other intersecting pathways (e.g., NF-κB, JNK) may also contribute to microglial regulation in vivo.
• Therapeutic Translation: While TREM2 emerges as a candidate target, direct interventions or small molecules modulating its activity in human uveitis are not addressed.

Therefore, while the molecular insights are robust within the EAU context, further studies in human tissue and with expanded pathway profiling are needed to support translational applications.

Protocol Parameters

• EAU induction: Employ standard immunization protocols with retinal autoantigen and adjuvant for consistent disease onset in murine models.
• TREM2 modulation: Apply lentiviral or plasmid-based transfection for overexpression or knockdown in BV2 cells or primary microglia; confirm efficiency via RT-qPCR and Western blot.
• Signaling pathway analysis: Use phospho-specific antibodies for ERK1/2 and p38 detection by Western blot at defined post-stimulation intervals.
• Immune cell profiling: Analyze retinal and splenic single-cell suspensions by flow cytometry for Th1, Th17, and Treg populations using canonical surface and intracellular markers.
• Transcriptomic profiling: Conduct RNA-seq on retinal tissue at peak disease for high-resolution mapping of TREM2-dependent gene expression changes.

Research Support Resources

For researchers aiming to dissect immune response modulation in dendritic cells, microglia, or model complex autoimmune processes, high-purity immunological tools are essential. Pertussis toxin (SKU B7273) from APExBIO offers a well-characterized AB5-type protein exotoxin for experimental immune modulation, including cAMP signaling pathway studies, TH17 polarization, and as a component in acellular pertussis vaccine models. The product’s high purity and compatibility with in vitro and in vivo assays make it a robust option for workflow replication and mechanistic exploration in alignment with the approaches outlined in the reference study.